Sign in to download the Issue in PDF format.
This paper has no abstract.
Cite this article as: de Carvalho JF, Lerner A. Malic Acid for Treatment of Rheumatic Diseases. Mediterr J Rheumatol 2023;Mediterr J Rheumatol 2023;34(4):592-3
Article Submitted: 29 Jun 2023; Revised Form: 01 Nov 2023; Article Accepted: 09 Nov 2023; Available Online: 30 Dec 2023
This work is licensed under a Creative Commons Attribution 4.0 International License.
©2023 The Author(s).
Malic acid (MA) is an intermediate compound of tricarboxylic acid cycle (TCA) and its addition could increase energy production. There are few articles demonstrating efficacy with low toxicity of MA supplementation in fibromyalgia (FM).1,2 Therefore, in this aspect, a systematic review of all articles published that evaluated the role of MA supplementation in rheumatic disease was presently conducted.
Following PRISMA guidelines, an extensive literature search in PubMed, Scielo, and LILACS was performed without any language restriction, from 1965 to March 2023. After a review of titles and abstracts, only three articles were selected for this review.
Those three articles are summarized in Table 1.1,3,4 The articles evaluated the effects of MA in Sjogren’s syndrome (SS) and FM with a total of 114 patients (190 SS and 24 in FM). Female patients were dominated, and ages varied from 56.17 to 58.5 years. All three studies were randomised controlled trials. In SS, MA was given as stimulatory saliva tapioca drug and in FM oral capsules were given to the patients. All trials showed an improvement in the clinical pictures, including the salivary flow and improvement of xerostomia symptoms in SS; and a decrease in FM symptoms was noted. No side effects were identified.
There are some other articles in the literature showing efficacy of topical MA in patients with xerostomia. In fact, a metanalysis on this field including 5 articles with 244 patients with xerostomia receiving topical sialagogue spray (malic acid 1%) or placebo.5 The authors evaluated and analysed weather topical sialagogue spray (malic acid 1%) improved the symptoms of dry mouth significantly better than the placebo, evaluated by the following questionnaires: Dry Mouth Questionnaire (DMQ), Xerostomia Inventory (XI), and Visual Analogue Scale (VAS) scores. Furthermore, an increase in unstimulated and stimulated saliva flow rates was also seen in treated SS patients applying MA.4 The suggested mechanism of action of MA, to improve salivary flow, is that after using a spray containing malic acid 1%, the hydrogen ion (H+) dissociates from malic acid to bind water (H2O), generating hydronium ions (H3O+). Then, H3O+ stimulates the secretion of saliva from salivary glands to neutralise acid, thereby improving dry mouth.5
The present study's strengths are: 1. the inclusion of all studies on MA in rheumatic conditions; 2. the use of international criteria for rheumatic diseases; 3. an extensive, long-term, and multilingual literature search was performed. The limitations are the detection of only few studies. Therefore, future well designed studies using MA in rheumatic conditions are desired to confirm the present data and expand on other rheumatic diseases.
In conclusion, only a few studies evaluated the role of malic acid in rheumatic diseases like SS and FM. Future well designed, using MA in rheumatic conditions, are highly desired to confirm the present data and expand on other rheumatic diseases.
The authors have no conflicts of interest to declare.
None.
